PDCD1 and cancer: A Phase II trial combining MEDI0457 and durvalumab in HPV-16/18-associated cancers reported an overall response rate (ORR) of 21%, while single-agent anti-PD1/PD-L1 therapies in anal squamous cell carcinoma (SCCA) have shown response rates of approximately 10–15% [83].